Flovuxin
ATC code
Species
Cattle
Indications
Treatment of respiratory infections caused by Mannheimia haemolytica, Pasteurella multocida, Mycoplasma bovis and Histophilus somni associated with pyrexia.
Dose to be administered and administration route
Subcutaneous use.
40 mg of florfenicol per kg bodyweight and 2.2 mg of flunixin per kg bodyweight (equivalent to 2 mL of product per 15 kg body weight) to be administered by a single subcutaneous injection.
The dose volume given at any one injection site should not exceed 10mL.
The cap may be safely punctured up to 25 times. When treating groups of animals in one run, use a draw-off needle that has been placed in the vial stopper to avoid excess broaching of the stopper. The draw-off needle should be removed after treatment. It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment 48 hours after injection. The anti-inflammatory component of this veterinary product, flunixin, may mask resistance to florfenicol in the first 24 hours after injection. If clinical signs of respiratory disease persist or increase, or if relapse occurs, treatment should be changed, using another antibiotic, and continued until clinical signs have resolved.
The injection should only be given in the neck.
Swab septum before removing each dose. Use a dry sterile needle and syringe.
To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.
Adverse reactions
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Anaphylactic-type reaction1 |
|
Undetermined frequency |
Application site swelling2 |
1Those reactions might be fatal.
2Subcutaneous administration of the product may result in application site swelling that become palpable 2-3 days after injection. The duration of the application site swelling ranged from 15-36 days post-injection. Grossly, this is associated with minimal to mild irritation of the subcutis. Extension into the underlying muscle was noted in only a few instances. By 56 days post-dosing, no gross lesions were observed that would require any trim-out at slaughter.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section 16 of the package leaflet for respective contact details.
References
Similar products
Showing 1 of 1 results
